表紙
市場調查報告書

青光眼手術設備報告 (2017年):全球市場分析 2016-2022年

2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024

出版商 Market Scope, LLC 商品編碼 644809
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
青光眼手術設備報告 (2017年):全球市場分析 2016-2022年 2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024
出版日期: 2019年08月14日內容資訊: 英文
簡介

一般認為帶來 本報告提供全球青光眼手術設備市場相關調查,盛行率與預測,外科介入所扮演的角色,目前正發售的產品的市場動態,及改善預後的研究階段設備的開發平台等的分析,產品需求的預測 (以數量、金額為準) 、各類別產品的市場佔有率分析,主要策略的課題相關討論等彙整資料。

簡介

摘要整理

關於青光眼

青光眼的盛行率

青光眼的治療供應商

  • 供應商,診斷,治療概要
  • 治療供應商及診斷設施
  • 美國的供應商
  • 西歐的供應商
  • 日本的供應商、其他

青光眼的診斷

  • 眼壓檢測
  • 角膜厚檢測
  • 視野檢測
  • 眼底鏡檢驗
  • 眼底攝影
  • 光學同調斷層掃瞄 (OCT)
  • 共焦掃描型雷射眼底鏡、其他

青光眼的治療

  • 治療方法
  • 處方藥
  • 開角型青光眼的治療
  • 高眼壓症患者的IOP治療
  • 剝離性青光眼/疑似紅斑青光眼的治療
  • 隅角閉鎖性青光眼
  • 目前藥物療法的限制
  • 青光眼介紹給專醫
  • 雷射與外科手術、其他

青光眼管理的課題

  • IOP的主要的作用
  • IOP及青光眼相關競爭理論
  • 青光眼治療選項擴大
  • 眼科醫生決定最好的POAG治療選項的方法
  • POAG階段及典型性的治療方法

雷射產品

  • 雷射小梁網整型術
  • 氬雷射小梁網整型術 (ALT)
  • 選擇的雷射小梁網整型術 (SLT)
  • 小梁網整型術的藥物療法的削減
  • 多雷射治療方法的頻率
  • 雷射週邊虹膜解剖術 (PI)
  • 角落方形成術 (虹膜形成) 等

青光眼的外科手術治療

  • 全球青光眼外科手術:各國/各地區
  • 青光眼外科手術的定位
  • 全球青光眼外科手術預測
  • 已外科治療青光眼患者人口比率的增加

傳統的青光眼外科手術 (CGS)

  • 過濾手術 (小梁網切除術)
  • 小梁網切除術的效果相關資料
  • 過濾手術的種類、數量
  • 醫療費償付

小梁網切除術的附屬產品

白內障手術的IOP (眼壓) 降低硬化

青光眼外科手術設備的先進技術

微創青光眼外科手術 (MIGS) 支架

管手術設備

  • 法規情形
  • (青光眼手術) 管狀成術
  • 近幾年臨床實驗結果
  • 法規,醫療費償付及市場情況
  • 管狀成術產品的預測、其他

小梁網切除 (Trab) Plus設備

  • 臨床結果
  • 其他青光眼外科手術設備

一次性物品

  • 一次性物品的市場預測
  • 競爭企業

可重複使用外科手術設備、小刀

企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

What's New:

‘The 2019 Glaucoma Surgical Device Market Report’ includes a new section on devices that deliver sustained release of medications and a deep dive analysis of the Alcon CyPass recall that occurred in 2018 and its impact on adoption of minimally invasive glaucoma surgery (MIGS) stents.

‘The 2019 Glaucoma Surgical Device Market Report’ offers a comprehensive analysis of the 2019 global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category.

Also in this report:

  • Deep dive analysis of the Alcon CyPass recall that occurred in 2018 and its impact on adoption of minimally invasive glaucoma surgery (MIGS) stents
  • We divide the 4 basic surgery categories into 15 different product types which are profiled
  • Analysis on the percentage of the different types of glaucoma surgeries being performed by US cataract surgeons, glaucoma specialists, and general ophthalmologists
  • New section on key opinion leaders' decision making on glaucoma surgery options
  • Background information about glaucoma, glaucoma populations, and glaucoma diagnosis
  • Estimates of current sales and sales forecasts for glaucoma devices, including average prices and total revenue.
  • Profiles of prospective device buyers, including ophthalmologists, ophthalmic specialists, optometrists, and general medical doctors
  • Information about manufacturers
  • Current reimbursement rates
  • Updated total global glaucoma populations for POAG, PACG, secondary and pediatric glaucoma, and ocular hypertension in eight regions

The report also simplifies the glaucoma surgery categories to four (MIGS, TRABs, tubes, and canal surgery), identifies the MIGS pipeline stents that will drive surgery penetration in each of the stages of glaucoma, and lists 15 early-stage glaucoma surgery device development projects.

Our Process:

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

  • Our proprietary global disease population and demographic models
  • Analysis of company-published financial reports
  • Focused coverage of ophthalmic scientific research, business news, and other activities
  • Attendance and participation in worldwide ophthalmic meetings
  • Interviews and relationships with company executives and practicing physicians

Author Profile:

William Freeman

Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.

Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.

After leaving Mentor in 1999, Bill joined Market Scope in 2000 and now serves as executive vice president focusing on ophthalmic surgical cataract, retinal and glaucoma devices.

Back to Top